To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Phase 1 Completed 92 enrolled Suzhou Kintor Pharmaceutical Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a randomized, double-blind, vehicle-controlled, parallel group, phase 1 study to evaluate the Safety, Tolerability and PK of GT20029 in healthy subjects

Timeline

Start: 2021-07-25
Primary completion: 2022-08-15
Completion: 2023-04-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GT20029	Unknown	1 mg	Other
Subject	GT20029	Unknown	2 mg	Other
Subject	GT20029	Unknown	5 mg	Other
Subject	GT20029	Unknown	10 mg	Other
Subject	GT20029	Unknown	20 mg	Other

To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Summary

Timeline

Drugs

Indications